162 related articles for article (PubMed ID: 37773814)
1. The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus.
Akyay OZ; Canturk Z; Selek A; Cetinarslan B; Tarkun İ; Cakmak Y; Baydemir C
Medicine (Baltimore); 2023 Sep; 102(39):e35394. PubMed ID: 37773814
[TBL] [Abstract][Full Text] [Related]
2. Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.
Cai TT; Li HQ; Jiang LL; Wang HY; Luo MH; Su XF; Ma JH
Biomed Res Int; 2021; 2021():3361309. PubMed ID: 34580638
[TBL] [Abstract][Full Text] [Related]
3. Association of genetic polymorphisms of RANK, RANKL and OPG with bone mineral density in Chinese peri- and postmenopausal women.
Shang M; Lin L; Cui H
Clin Biochem; 2013 Oct; 46(15):1493-501. PubMed ID: 23531404
[TBL] [Abstract][Full Text] [Related]
4. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men.
Roshandel D; Holliday KL; Pye SR; Boonen S; Borghs H; Vanderschueren D; Huhtaniemi IT; Adams JE; Ward KA; Bartfai G; Casanueva F; Finn JD; Forti G; Giwercman A; Han TS; Kula K; Lean ME; Pendleton N; Punab M; Silman AJ; Wu FC; Thomson W; O'Neill TW;
J Bone Miner Res; 2010 Aug; 25(8):1830-8. PubMed ID: 20205168
[TBL] [Abstract][Full Text] [Related]
6. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
7. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
8. Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women.
Zupan J; Mencej-Bedrac S; Jurković-Mlakar S; Prezelj J; Marc J
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):102-6. PubMed ID: 19896533
[TBL] [Abstract][Full Text] [Related]
9. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
10. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
Mezquita-Raya P; de la Higuera M; García DF; Alonso G; Ruiz-Requena ME; de Dios Luna J; Escobar-Jiménez F; Muñoz-Torres M
Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
[TBL] [Abstract][Full Text] [Related]
11. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
12. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
D'Amore M; Fanelli M; D'Amore S; Fontana A; Minenna G
Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes.
Liu L; Yan H; Xia M; Zhao L; Lv M; Zhao N; Rao S; Yao X; Wu W; Pan B; Bian H; Gao X
Diabetes Metab Res Rev; 2020 Jul; 36(5):e3292. PubMed ID: 31955491
[TBL] [Abstract][Full Text] [Related]
14. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
15. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
[TBL] [Abstract][Full Text] [Related]
16. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.
Fernández-García D; Muñoz-Torres M; Mezquita-Raya P; de la Higuera M; Alonso G; Reyes-García R; Ochoa AS; Ruiz-Requena ME; Luna JD; Escobar-Jiménez F
J Endocrinol Invest; 2008 May; 31(5):416-21. PubMed ID: 18560259
[TBL] [Abstract][Full Text] [Related]
17. Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway.
Ma B; Zhang Q; Wu D; Wang YL; Hu YY; Cheng YP; Yang ZD; Zheng YY; Ying HJ
Acta Pharmacol Sin; 2012 Apr; 33(4):479-89. PubMed ID: 22426695
[TBL] [Abstract][Full Text] [Related]
18. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers.
Gurkan E; Tarkun I; Sahin T; Cetinarslan B; Canturk Z
Diabetes Res Clin Pract; 2014 Dec; 106(3):567-75. PubMed ID: 25458329
[TBL] [Abstract][Full Text] [Related]
20. Oral Exposure to ZnO Nanoparticles Disrupt the Structure of Bone in Young Rats via the OPG/RANK/RANKL/IGF-1 Pathway.
Xu X; Tang Y; Lang Y; Liu Y; Cheng W; Xu H; Liu Y
Int J Nanomedicine; 2020; 15():9657-9668. PubMed ID: 33299310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
